Summary & Overview
CPT 78812: FDG PET Body Imaging for Oncologic Evaluation
CPT code 78812 represents FDG positron emission tomography (PET) imaging used to detect metabolic activity consistent with malignancy and to visualize three-dimensional distributions of radiotracer uptake. Nationally, FDG-PET plays a central role in cancer diagnosis, staging, and surveillance because it identifies hypermetabolic lesions that may not be apparent on anatomic imaging alone. The code captures a diagnostic imaging service that informs clinical decision-making across oncology, radiation planning, and systemic therapy assessment.
Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for PET imaging with FDG, typical sites of service, and the operational implications for providers and imaging centers. The publication also summarizes reimbursement benchmarks, common billing modifiers, and payer coverage considerations where available. Policy updates that affect coverage criteria and utilization management for FDG-PET imaging are highlighted, along with practical notes on documentation elements that support medical necessity. This resource is designed for clinicians, billing professionals, and policy analysts seeking a national perspective on use and billing of FDG-PET imaging under CPT code 78812.
Billing Code Overview
CPT code 78812 describes a positron emission tomography (PET) imaging study using the radiopharmaceutical fluorodeoxyglucose (FDG) to produce three-dimensional images that detect areas of increased metabolic activity, commonly used to identify malignant tumors. The procedure involves injection of FDG prior to imaging and capture of photon emissions by a PET scanner, producing images that highlight tissues with high radiotracer uptake.
Service Type: Diagnostic imaging (FDG-PET)
Typical Site of Service: Hospital outpatient department or dedicated imaging center
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with a history of non-small cell lung cancer presents for surveillance imaging after systemic therapy to assess for residual or recurrent disease and to stage suspected metastatic spread. The patient arrives at the nuclear medicine department after fasting for at least 4–6 hours and having a blood glucose check; an intravenous line is placed. The patient is injected with FDG (fluoro-deoxyglucose) approximately one hour prior to imaging to allow systemic distribution and uptake by metabolically active tissues. The PET/CT scanner acquires three-dimensional images capturing photon emissions from FDG uptake; images are reconstructed and reviewed by a nuclear medicine physician or radiologist for focal areas of increased uptake consistent with malignancy. The imaging encounter includes radiopharmaceutical preparation and administration, patient monitoring during uptake, image acquisition, image reconstruction, and interpretation with a written report provided to the referring oncologist.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | When billing only the interpreting physician’s professional reading of the PET images separate from technical component |
TC |